Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2025Journal of Clinical InvestigationOpen Access

KRAS: the Achilles’ heel of pancreas cancer biology

View Full Paper
Ask AI
Bookmark
Share

Authors

KDKristina Drizyte‐MillerTTTaiwo TalabiASAshwin Somasundaram

Discussion

Loading...

Member takes

Overview

Review highlights the role of kras mutations and challenges in targeting these for pancreatic cancer treatment.

Key Points

  • KRAS mutation is essential for tumorigenic and metastatic growth in pancreatic ductal adenocarcinoma.
  • About 95% of pancreatic ductal adenocarcinoma cases harbor KRAS mutations, underscoring its significance.
  • Summary of anti-KRAS treatment strategies reveals ongoing challenges in effectively targeting KRAS for therapy.
  • Approval of KRAS inhibitors for other cancers suggests potential breakthroughs for pancreatic cancer treatment.

Cite This Study

Drizyte‐Miller et al. (2025) studied this question.

synapsesocial.com/papers/68af33efcf1dd9ea359e96e5https://doi.org/10.1172/jci191939
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pancreatic cells are resistant to KRAS(Q61L) expression due to hyperactive ERK/MAPK signaling and apoptosis induction2025
  2. 2Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise2025
  3. 3KRASG12D in Cancer: Structural Insights, Signaling Pathways, and Progress in Targeted Inhibitor Design2025
  4. 4Drivers of Pancreatic Cancer: Beyond the Big 42025
  5. 5KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges2025 · 5 citations